跳转至内容
Merck
所有图片(1)

主要文件

Y0001034

利奈孕酮

European Pharmacopoeia (EP) Reference Standard

别名:

Lynestrenol, (17α)-19-Norpregn-4-en-20-yn-17-ol

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C20H28O
CAS号:
分子量:
284.44
分類程式碼代碼:
41116107
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

lynestrenol

製造商/商標名

EDQM

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

2-8°C

InChI

1S/C20H28O/c1-3-20(21)13-11-18-17-9-8-14-6-4-5-7-15(14)16(17)10-12-19(18,20)2/h1,6,15-18,21H,4-5,7-13H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1

InChI 密鑰

YNVGQYHLRCDXFQ-XGXHKTLJSA-N

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Lynestrenol for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

M Iqbal Choudhary et al.
Natural product research, 24(1), 1-6 (2009-12-17)
Transformation of lynestrenol (19-nor-17alpha-pregn-4-en-20-yn-17beta-ol) (1) was carried out by incubation with Cunninghamella elegans to obtain 19-nor-17alpha-pregn-4-en-20-yn-3-one-10beta,17beta-diol (2), 19-nor-17alpha-pregn-4-en-20-yn-3-one-6beta,17beta-diol (3), and 19-nor-17alpha-pregn-4-en-20-yn-3beta,6beta,17beta-triol (4). Metabolite 4 was identified as a new compound. These metabolites were structurally characterised on the basis of spectroscopic
Dominik Rachoń et al.
Menopause (New York, N.Y.), 13(5), 840-845 (2006-08-09)
Oral estrogen increases the levels of C-reactive protein (CRP), which is an independent risk factor for coronary heart disease in healthy individuals. The aim of our study was to investigate the effects of intranasal 17beta-estradiol (E2) on serum CRP and
Venous thromboembolism after high-dose chemotherapy in a patient with Hodgkin's lymphoma receiving the new oral contraceptive ethinylestradiol and drospirenone ("Yasmine").
A Tartarone et al.
Bone marrow transplantation, 35(1), 103-103 (2004-11-09)
Ofer Amir et al.
Journal of speech, language, and hearing research : JSLHR, 49(5), 1114-1126 (2006-11-02)
Two studies are presented here. Study 1 was aimed at evaluating whether the voice characteristics of women who use birth control pills that contain different progestins differ from the voice characteristics of a control group. Study 2 presents a meta-analysis
Sidsel Graff-Iversen et al.
Contraception, 66(1), 7-13 (2002-08-10)
This population-based cross-sectional study assessed lipid and lipoprotein parameters in women using progestogen-only contraceptives or medications and in those using no hormones. Unselected women about age 40 to 42 years were invited, and the participation rate was 65.6%. A total

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门